Pancragen
/ Khavinson-tradition tetrapeptide (Lys-Glu-Asp-Trp); proposed pancreatic islet bioregulatorALIAS · KEDW · Lys-Glu-Asp-Trp · Pancreatic peptide bioregulator
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Khavinson-tradition tetrapeptide Lys-Glu-Asp-Trp (KEDW) marketed as a pancreatic-islet bioregulator. The Khavinson group has published in-vitro and small-animal work on KEDW effects on pancreatic-cell gene expression and insulin-pathway markers; this literature has not been independently replicated in Western laboratories.
Pancragen is the synthetic tetrapeptide Lys-Glu-Asp-Trp (KEDW). Within the Khavinson-tradition framework the proposed mechanism is tissue-specific regulation of pancreatic islet cells via direct interaction with promoter regions of insulin-pathway and differentiation-related genes. Reported effects in the Khavinson literature include modulation of insulin and PDX-1 expression in pancreatic cell preparations.
Tier 4. PubMed-indexed primary literature is sparse and from the Khavinson group; principally in-vitro pancreatic cell work and rodent ageing models. No human clinical-trial data.
No formal human safety database. The pancreatic-tissue-targeted claim implies effects on insulin / glucose homeostasis that are not characterised in published Western literature; subjects with diabetes or glucose-regulation disorders cannot be assessed for interaction risk from the available record.
Regulatory status
- FDA status:
- Not FDA-approved
The Khavinson school (Saint-Petersburg Institute of Bioregulation and Gerontology) has published an extensive body of work on short-peptide 'bioregulators' derived from animal-tissue extracts, with a unifying claim that tissue-specific tetrapeptides (and shorter motifs) regulate gene expression and tissue-specific cell function. The corpus is Russian-origin and substantially self-cited; independent Western replication of the foundational findings has not been established.
The pancreatic-islet regulation claim is mechanistically specific (insulin / PDX-1 modulation) but rests on a small, originating-group literature without independent replication. Vendor-sold KEDW is not comparable to a regulated pharmaceutical preparation with characterised pharmacokinetics.